Propofol Up-regulates MicroRNA-30b to repress Beclin-1 and Inhibits Excessive Autophagy and Apoptosis

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-14005470

Enrollment

Unknown

Registered

2014-10-07

Start date

2014-11-10

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemia reperfusion

Interventions

Propofol group:Propofol

control group :sevoflurane

Eligibility

Sex/Gender

All

Age

35 Years to 65 Years

Inclusion criteria

Inclusion criteria: ASA physical status II or III scheduled for mitral valve replacement surgery, were allocated to control group and propofol group. Eligible subjects were 20 to 65 years old. Patients did not appear myocardial relevant enzyme increasing 24h before the operation,besides prohibite dosing sevoflurane and propofol 28d before the surgery. Patients didn't serious liver, kidney dysfunction and so on. Ejection fraction should exceed 0.30. The patient has no known anesthetic drug allergy.

Exclusion criteria

Exclusion criteria: 1. serious organ disorder;Ejection fraction less than 0.3; 2. Patients appeared myocardial relevant enzyme increasing 24h before the operation. 3. The patients prohibites dosing sevoflurane and propofol during 28d before the surgery.

Design outcomes

Primary

Measure	Time frame
beclin-1;LC3;microRNA-30b;	—

Countries

China

Contacts

Public ContactLiangqing Zhang

zhanglq1970@163.com+86 13822586877

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 13, 2026